Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
- PMID: 33603610
- PMCID: PMC7874880
- DOI: 10.5114/ada.2019.84746
Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
Abstract
Introduction: Systemic sclerosis (SSc) is an autoimmune connective tissue disease with distinguished fibrosis of the skin and internal organs. Vascular damage, immune dysregulation and fibroblasts activation contribute to SSc pathogenesis. Peroxisome proliferator-activated receptor γ (PPAR-γ) can be a link between cell metabolism and fibrosis in SSc due to its anti-fibrotic and immunomodulatory properties.
Aim: To measure the serum level of PPAR-γ in SSc patients and correlate it with the SSc subtype, hs-CRP, disease duration, vascular and internal organ involvement.
Material and methods: Twenty-two SSc patients (15 limited SSc, 7 diffuse SSc) matched with healthy controls were analysed. Clinical and laboratory data were collected including specific antibodies, interstitial lung disease, oesophageal involvement, digital pitting scars, disease duration, Raynaud's phenomenon (RP) and modified Rodnan skin score (mRSS). PPAR-γ levels were analysed by ELISA. Statistical analysis was performed with χ2, Student's t-test and Mann-Whitney-U test. Pearson and Spearman correlation analyses were used to establish variables association. The significance threshold was set at p < 0.05.
Results: PPAR-γ concentration was elevated in SSc patients in comparison to controls (p = 0.007) with the highest difference for diffuseSSc (p = 0.004) with significantly elevated mRSS. No association between PPAR-γ levels and hs-CRP, internal organ and vascular involvement, disease duration, autoantibodies and RP onset was found.
Conclusions: The present study revealed elevated serum PPAR-γ in SSc patients, in particular those with a diffuse form, presenting highest mRSS and lowest BMI. Whether circulating PPAR-γ originates from atrophic adipose tissue, reperfused vessels or ischemic tissues needs assessing. Also the biological meaning or effect of elevated serum PPAR-γ requires further studies.
Keywords: fibrosis; organ involvement; peroxisome proliferator-activated receptor γ; pits; systemic sclerosis.
Copyright: © 2019 Termedia Sp. z o. o.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Serum concentration of angiopoietin-like protein 4 in patients with systemic sclerosis.Pol Merkur Lekarski. 2021 Feb 24;49(289):28-31. Pol Merkur Lekarski. 2021. PMID: 33713089
-
Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?Arthritis Res Ther. 2012 May 1;14(3):R102. doi: 10.1186/ar3827. Arthritis Res Ther. 2012. PMID: 22548780 Free PMC article.
-
[Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis].Beijing Da Xue Xue Bao Yi Xue Ban. 2020 Dec 18;52(6):1009-1013. doi: 10.19723/j.issn.1671-167X.2020.06.004. Beijing Da Xue Xue Bao Yi Xue Ban. 2020. PMID: 33331306 Free PMC article. Chinese.
-
The Updated Role of Ultrasound in Assessing Dermatological Manifestations in Systemic Sclerosis.Open Access Rheumatol. 2021 Apr 28;13:79-91. doi: 10.2147/OARRR.S282612. eCollection 2021. Open Access Rheumatol. 2021. PMID: 33953621 Free PMC article. Review.
-
Systemic sclerosis and the gastrointestinal tract.Prz Gastroenterol. 2017;12(3):163-168. doi: 10.5114/pg.2017.70467. Epub 2017 Sep 30. Prz Gastroenterol. 2017. PMID: 29123575 Free PMC article. Review.
Cited by
-
Interplay of NF-κB and PPAR-γ transcription factors in patients with juvenile systemic lupus erythematosus.Lupus Sci Med. 2025 Jan 8;12(1):e001263. doi: 10.1136/lupus-2024-001263. Lupus Sci Med. 2025. PMID: 39779243 Free PMC article.
-
Molecular crosstalk in perivascular adipose tissue: mechanisms of inflammation, metabolic dysregulation, and therapeutic opportunities in cardiovascular disease.Front Cardiovasc Med. 2025 Jun 26;12:1613900. doi: 10.3389/fcvm.2025.1613900. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40642747 Free PMC article. Review.
-
Lipid Alterations in Systemic Sclerosis.Front Mol Biosci. 2021 Dec 21;8:761721. doi: 10.3389/fmolb.2021.761721. eCollection 2021. Front Mol Biosci. 2021. PMID: 34993231 Free PMC article. Review.
-
Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.J Inflamm Res. 2023 Oct 17;16:4633-4660. doi: 10.2147/JIR.S379815. eCollection 2023. J Inflamm Res. 2023. PMID: 37868834 Free PMC article. Review.
References
-
- Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. - PubMed
-
- Zhu H, Chen W, Liu D, Luo H. The role of metabolism in the pathogenesis of systemic sclerosis. Metabolism. 2019;93:44–51. - PubMed
-
- Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol. 2019;15:208–24. - PubMed
-
- Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle. 2007;6:1539–48. - PubMed
-
- Umemoto T, Fujiki Y. Ligand-dependent nucleo-cytoplasmic shuttling of peroxisome proliferator-activated receptors, PPARalpha and PPARgamma. Genes Cells. 2012;17:576–96. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous